Form 4: Director Ian F. Smith Receives Odyssey Therapeutics Options

Director Ian F. Smith was granted 27,393 stock options in Odyssey Therapeutics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Ian F. Smith acquired 27,393 stock options in Odyssey Therapeutics, Inc. (ODTX).
• The options have an exercise price of $18.00 per share.
• The grant date for these options is May 7, 2026.
• The options are scheduled to vest in full on May 7, 2027, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation, which carries no significant signal regarding company performance.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is subject to the continued service of the director, creating a dependency on personnel retention.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of an equity grant to a director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector, intended to incentivize board members and align their interests with long-term company performance.

Comparison to Industry Standards

• The use of time-based vesting (one-year cliff) is consistent with standard equity compensation practices for non-employee directors in the life sciences industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 7, 2027.

Key Dates

Keywords

Odyssey Therapeutics, ODTX, Form 4, Insider Trading, Stock Options, Director Compensation